Takara Shuzo Co., Inc.

Takara Bio Inc.

Kazutoh Takesako

Ikunoshin Kato

Takashi Okado

Naoyuki Awazu

Hideyo Yamaguchi

Toru Kurome

Teruya Nakamura

Kazuo Shimanaka

Katsushige Ikai

Junko Yamamoto

Mitsuhiro Ueno

Yoshimi Onishi

Fumiyo Haruna

Katsuhisa Uchida

Kaoru Inami

Masahiro Endo

Shigetoshi Mizutani

Tomoko Yagihara

Masanobu Kuroda

Kazuo Akiyama

Hiroshi Yasueda

Junichi Mineno

Tetsuo Shiba

Hideto Chono

Hideharu Saito

Hiroaki Sagawa

Nobuto Koyama

Takao Yoshida

Akira Obayashi

Teruhiko Beppu

Hirofumi Yoshioka

Yoshie Yoshikawa

Eiko Koyama

Kazuya Matsumoto

Masao Funakoshi

Yasushi Katayama

Yoko Uno

Takashi Morimura

Kenji Sakai

Shin-ichi Yamada

Tetsuya Inoue

Takashi Okada

Noritsugu Yabe

Daisuke Tomura

Yuko Taguchi

Junko Ogawa

The present invention provides a baglike container for centrifugation that is mounted in a centrifuge to thereby allow centrifugation of a dispersion liquid accommodated therein. The baglike container for centrifugation is less likely to tear or break as a result of centrifugation by disposing a container wall surface of the baglike container so as to apply centrifugal force perpendicular to the container wall surface.

Baglike container for centrifugation and method of gene transfer using the same

There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.

Fungal antigens and process for producing the same

A substantially pure, isolated, antigenic protein from fungi of the genus, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug forallergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

[object Object]

A method for obtaining a virus vector free of a serum, and a serum-free medium for cultivation of a virus producer cell which can be used for the method are provided. By cultivating a virus producer cell using a serum-free medium containing serum albumin, it is possible to cultivate the cell in a state equivalent to that in a serum-containing medium to produce a virus vector at a sufficient titer. The virus vector prepared from the virus producer cell cultivated in the medium exhibits gene transfer efficiency comparable to that of a conventional vector. The medium is useful for gene therapy and studies thereof.

Serum-free medium for producing retroviruses

A novel cyclic peptide having an antifungal activity, its pharmacologically acceptable salts and antifungal medicinal compositions containing the same.

Cyclic peptide

To provide a novel antigenic protein and a nucleic acid encoding the antigenic protein, which are useful for prophylaxis, treatment and diagnosis of diseases caused by fungi including. An antigenic protein characterized in that the antigenic protein is recognized by antiserum derived from a mammal having-infection resistance; and a nucleic acid encoding an antigenic protein which is recognized by antiserum derived from a mammal having-infection resistance.

Antigen protein and nucleic acid coding for said protein

A substantially pure, isolated, antigenic protein from fungi of the genus, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergies; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug forallergies, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Antigenic protein originating in malassezia

The invention is directed to isolated DNAs having nucleic acid sequences which encode proteins which regulate aureobasidin sensitivity. Also disclosed are recombinant plasmids containing the DNAs, transformants containing the plasmids, and methods of producing the proteins.

Gene regulating aureobasidin sensitivity

An antiviral agent which is characterized in containing at least one compound selected from a group consisting of 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula &lsqb;I&rsqb; and an optically active substance and a salt thereof as an effective component.

Antiviral agents

A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

The invention provides an isolated gene coding for a protein regulating aureobasidin sensitivity; a process for cloning the gene with the use of the gene or a part of the same as a probe; a nucleic acid probe being hybridizable with the gene; an antisense DNA or RNA of the gene; a recombinant or transformant having the gene contained therein; an isolated protein regulating aureobasidin sensitivity and a process for producing the same by using the transformant; an antibody for the protein; a process for detecting the protein or the gene; and a process for screening an antimycotic by using the protein or the transformant. The invention is useful in the diagnosis and treatment of diseases including mycoses.

Processes of screening for an antimycotic agent

The present invention provides a protein regulating the sensitivity of fungus to an antimycotic aureobasidin, a gene coding for this protein, the use thereof, an antibody for the protein and the use thereof. The invention is useful in the diagnosis and treatment for diseases including mycoses. The invention also provides a novel chromosome integration vector capable of imparting a novel selective marker of a drug resistance to a fungal transformant, a transformant transformed with this vector and a process for producing the same. In particular, it provides a protein capable of imparting the resistance to aureobasidin and acting as a selective marker and a DNA coding for the same.

Regulation of aureobasidin sensitivity in fungus

Antibiotic TKR459, production method, and microorganism

Antibiotic TKR2999, process for the preparation thereof and microbe

Growing community of inventors

Otsu, Japan

Kazutoh Takesako